CCM
APLS

Camber Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Camber Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$14.7M Buy
+850,000
New +$15.7M 1.38% 17

Other funds holding APLS

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Camber Capital Management's APLS Position: Q2 2025 in Review

Camber Capital Management opened a new position in Apellis Pharmaceuticals (APLS) in Q2 2025: 850,000 shares worth $14.7M. The stake represents 1.38% of the portfolio and ranks #17 among its holdings.

247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.

  • Camber Capital Management held 850,000 shares of Apellis Pharmaceuticals worth $14.7M as of Q2 2025.
  • Apellis Pharmaceuticals was a new Camber Capital Management position in Q2 2025.
  • Apellis Pharmaceuticals made up 1.38% of Camber Capital Management's portfolio in Q2 2025, its #17 holding.
  • 247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.